Injectables Manufacturing

ARTICLES

  • What Beer Can Teach Us About Outsourcing

    I’m not a biologist or chemist, but apply these disciplines to beer and my interest is immediately piqued. Mix in a discussion of outsourcing – contract brewing, if you will – and we add a dose of professional relevance as well. Yes, this article is related to the pharma industry, so stay with me here if the beer reference didn't wet your thirst.

    First, though, an anecdote about the beer. It starts years ago when the production of my favorite brew was outsourced abroad to serve international markets. The taste never matched up to the original, as confirmed by aficionados of this brand around the world. I was recently reminded of this situation while reading a review in the Wall Street Journal of the new book The Craft Beer Revolution by Steve Hindy. For one thing, it appears outsourcing in the microbrew industry – the biotechs of beer – is being questioned. Would a microbrew from, for example, Brooklyn Brewery, be less than honest with its customers if they outsourced production far from the five boroughs?

  • Company Confronts, Conquers Capacity Crisis

    Upon acquiring several successful product lines from an established global company, a young U.S.generic and branded pharmaceutical manufacturer inherits more than 30 chargeback accounts, introducing a challenge well beyond its processing capacity.By DDN

SUPPLIER PROFILES

SERVICES

  • Pharmaceutical Development

    Developing an optimized formulation tailored to your API nanoparticles is critical to unlocking their full potential.

  • Aseptic Fill Finish

    One of the few CDMOs offering sterile fill, device manufacturing, and final assembly at one site — combining expertise, scale, and flexibility for clinical, commercial, and niche production.

NEWS

  • CEOs Say 505(b)(2) Pathway Will Drive Growth In Generic Industry
    2/27/2014

    To better understand where the generic market is heading, a panel discussion was held with CEOs of top generic pharmaceutical companies and key financial analysts at this year’s Generic Pharmaceutical Association (GPhA) annual meeting. This year, Ronny Gal, Ph.D., senior analyst with Sanford C. Bernstein, and Randall Stanicky, managing director for equity research with RBC Capital Markets, met with the CEOs of Mylan, Hospira, Teva, Apotex and Momenta.